Results 21 to 30 of about 63,877 (297)
Cyclooxygenase 2 (COX-2) inhibitors [PDF]
Ciklooksigenaza-2 (engl. Cyclooxygenase-2, COX-2) je enzim koji se pojavljuje u bolnim i upaljenim tkivima, dok je u zdravim tkivima uglavnom neaktivan.
Magić, Dina
core +2 more sources
Prostaglandins and inhibitors of their synthesis (cyclooxygenase (COX) inhibitors, non-steroidal anti-inflammatory drugs) were shown to play a significant role in the regulation of hematopoiesis. Partly due to their hematopoiesis-modulating effects, both
Michal Hofer +2 more
doaj +1 more source
Individualized ibuprofen treatment using serial B-type natriuretic peptide measurement for symptomatic patent ductus arteriosus in very preterm infants [PDF]
PurposePlasma level of B-type natriuretic peptide (BNP), an emerging, sensitive, and specific biomarker of hemodynamically significant patent ductus arteriosus (PDA), rapidly decreases in infants receiving cyclooxygenase inhibitors for ductal closure. We
Jeonghee Shin +4 more
doaj +1 more source
Update on Cyclooxygenase-2 Inhibitors [PDF]
Nonsteroidal anti-inflammatory drugs represent the most commonly used medications for the treatment of pain and inflammation, but numerous well-described side effects can limit their use. Cyclooxygenase-2 (COX-2) inhibitors were initially touted as a therapeutic strategy to avoid not only the gastrointestinal but also the renal and cardiovascular side ...
Raymond C, Harris, Matthew D, Breyer
openaire +2 more sources
Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs) : a systematic structured review of the literature [PDF]
Adverse events triggered by non-steroidal anti-inflammatory drugs (NSAIDs) are among the most common drug-related intolerance reactions in medicine; they are possibly related to inhibition of cyclooxygenase-1.
Weberschock, Tobias Bernd Bernd +8 more
core +1 more source
Nonsteroidal anti-inflammatory drugs and acetaminophen are cyclooxygenase inhibitors commonly used as symptomatic medicines for myofascial pain syndrome.
Tetsuhiro Shimodaira +2 more
doaj +1 more source
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer [PDF]
Background Selective cyclooxygenase inhibitors may retard the progression of cancer, but they have enhanced thrombotic potential. We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal ...
Christopher C. McConkey +36 more
core +1 more source
Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis [PDF]
Background: Squamous cell carcinoma of the head and neck (SCCHN) are highly invasive tumours with frequent local and distant recurrence. Metastasis formation requires degradation of the extracellular matrix, which is fulfilled by membrane-associated ...
Olivier Gires +31 more
core +1 more source
Effects of multiple-dose regimens (oral, daily, once a day for 15 days) of cyclooxygenase (COX) inhibitors etoricoxib (1 and 10 mg/kg), diclofenac sodium (1 and 5 mg/kg) and their combinations with 2-ethyl-6-methyl-3-hydroxypyridine succinate (mexidol 25
E. A. Ivanova +3 more
doaj +1 more source
Lipopolysaccharide is an inflammatory agent and interleukin-1 is a cytokine. Their pro-inflammatory effects may be mediated by prostanoids produced by inducible cyclooxygenase-2.
W. E. Longo +5 more
doaj +1 more source

